Financings Of The Fortnight: Is Google/Calico The Start Of A Wave Of Funding Alternatives?
This article was originally published in The Pink Sheet Daily
As survey respondents broadly expect venture capital activity to wane in the coming years, are Google and their like pointing to the next way of financing life sciences innovation? Plus news on recent financings by Civitas Therapeutics, DRI Capital, Five Prime Therapeutics and Cubist Pharmaceuticals.
You may also be interested in...
The Internet search and advertising giant has tapped Genentech and Apple chairman Art Levinson to lead a new initiative that will explore aging and related diseases. Google will invest an undisclosed amount to launch the latest Silicon Valley-funded effort to extend human longevity.
After a slow August and early September, Wall Street is preparing for four biotech IPOs. Biotech IPOs have been on fire, outperforming even the vigorous biotech indices. But the question remains – can public investors get too much of a good thing?
Toronto-based health care royalty acquirer raises a $1.45 billion third fund, which it says should last between three-and-a-half and five years. It is mainly sticking with its prior investment strategy, although for the first time DRI will look at acquiring royalty rights to promising Phase III candidates.